Literature DB >> 20837780

B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy.

Susan Moir1, Clarisa M Buckner, Jason Ho, Wei Wang, Jenny Chen, Amy J Waldner, Jacqueline G Posada, Lela Kardava, Marie A O'Shea, Shyam Kottilil, Tae-Wook Chun, Michael A Proschan, Anthony S Fauci.   

Abstract

Characterization of lymphocytes including B cells during early versus chronic HIV infection is important for understanding the impact of chronic viremia on immune cell function. In this setting, we investigated B cells before and after reduction of HIV plasma viremia by antiretroviral therapy (ART). At baseline, peripheral blood B-cell counts were significantly lower in both early and chronic HIV-infected individuals compared with uninfected controls. Similar to CD4(+) but not CD8(+) T cells, B-cell numbers in both groups increased significantly after ART. At baseline, B cells of early HIV-infected individuals were composed of a higher percentage of plasmablasts and resting memory B cells compared with chronic HIV-infected individuals whose B cells were composed of a higher percentage of immature/transitional and exhausted B cells compared with their early infection counterparts. At 1 year after ART, the percentage of resting memory B cells remained higher in early compared with chronic HIV-infected individuals. This difference translated into a better functional profile in that memory B-cell responses to HIV and non-HIV antigens were superior in early- compared with chronic-treated HIV infected individuals. These findings provide new insights on B cells in HIV infection and how early initiation of ART may prevent irreversible immune system damage.

Entities:  

Mesh:

Year:  2010        PMID: 20837780      PMCID: PMC3031405          DOI: 10.1182/blood-2010-05-285528

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy.

Authors:  F P Kroon; G F Rimmelzwaan; M T Roos; A D Osterhaus; D Hamann; F Miedema; J T van Dissel
Journal:  AIDS       Date:  1998-12-03       Impact factor: 4.177

2.  Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons.

Authors:  Edgar Turner Overton; Somnuek Sungkanuparph; William G Powderly; Warren Seyfried; Richard K Groger; Judith A Aberg
Journal:  Clin Infect Dis       Date:  2005-08-22       Impact factor: 9.079

3.  Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions.

Authors:  Kehmia Titanji; Francesca Chiodi; Rino Bellocco; Danika Schepis; Lyda Osorio; Chiara Tassandin; Giuseppe Tambussi; Sven Grutzmeier; Lucia Lopalco; Angelo De Milito
Journal:  AIDS       Date:  2005-11-18       Impact factor: 4.177

Review 4.  Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras.

Authors:  Maria Prins; Laurence Meyer; Nancy A Hessol
Journal:  AIDS       Date:  2005-03-04       Impact factor: 4.177

5.  The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.

Authors:  M Markowitz; M Vesanen; K Tenner-Racz; Y Cao; J M Binley; A Talal; A Hurley; X Jin; M R Chaudhry; M Yaman; S Frankel; M Heath-Chiozzi; J M Leonard; J P Moore; P Racz; D F Nixon; D D Ho; X J
Journal:  J Infect Dis       Date:  1999-03       Impact factor: 5.226

6.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

7.  Selective CD27+ (memory) B cell reduction and characteristic B cell alteration in drug-naive and HAART-treated HIV type 1-infected patients.

Authors:  Yong Chong; Hideyuki Ikematsu; Kensuke Kikuchi; Masahiro Yamamoto; Masayuki Murata; Mika Nishimura; Shigeki Nabeshima; Seizaburo Kashiwagi; Jun Hayashi
Journal:  AIDS Res Hum Retroviruses       Date:  2004-02       Impact factor: 2.205

8.  Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7.

Authors:  Angela Malaspina; Susan Moir; Jason Ho; Wei Wang; Melissa L Howell; Marie A O'Shea; Gregg A Roby; Catherine A Rehm; Joann M Mican; Tae-Wook Chun; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

9.  Identification of germinal center B cells in blood from HIV-infected drug-naive individuals in Central Africa.

Authors:  Lydie Béniguel; Evelyne Bégaud; Fabrice Cognasse; Philippe Gabrié; Christophe D Mbolidi; Odile Sabido; Mary A Marovich; Christiane DeFontaine; Anne Frésard; Frédéric Lucht; Christian Genin; Olivier Garraud
Journal:  Clin Dev Immunol       Date:  2004-03

10.  HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy.

Authors:  L Morris; J M Binley; B A Clas; S Bonhoeffer; T P Astill; R Kost; A Hurley; Y Cao; M Markowitz; D D Ho; J P Moore
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

View more
  127 in total

1.  Rapid HIV Progression Is Associated with Extensive Ongoing Somatic Hypermutation.

Authors:  Ben S Wendel; Yajing Fu; Chenfeng He; Stefany M Hernandez; Mingjuan Qu; Zining Zhang; Yongjun Jiang; Xiaoxu Han; Junjie Xu; Haibo Ding; Ning Jiang; Hong Shang
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

Review 2.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

Review 3.  Post-Treatment Controllers: Role in HIV "Cure" Research.

Authors:  Leslie R Cockerham; Hiroyu Hatano; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

4.  Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.

Authors:  Carolina B Ferreira; Alberto Merino-Mansilla; Anuska Llano; Ignacio Pérez; Isabel Crespo; Laia Llinas; Felipe Garcia; Jose M Gatell; Eloisa Yuste; Victor Sanchez-Merino
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

Review 5.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

6.  Effective B cell activation in vitro during viremic HIV-1 infection with surrogate T cell stimulation.

Authors:  Lindsay K Nicholson; Harsh Pratap; Elisabeth Bowers; Elise Gunzburger; Srinivasa R Bandi; Edward M Gardner; Brent E Palmer; Timothy Wright; John Kittelson; Edward N Janoff
Journal:  Immunobiology       Date:  2018-09-07       Impact factor: 3.144

7.  Antiretroviral therapy restores age-dependent loss of resting memory B cells in young HIV-infected Zambian children.

Authors:  Kaitlin Rainwater-Lovett; Hope C Nkamba; Mwnagelwa Mubiana-Mbewe; Carolyn B Moore; Joseph B Margolick; William J Moss
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

8.  Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.

Authors:  Cynthia L Gay; Sarah J Willis; Anna B Cope; JoAnn D Kuruc; Kara S McGee; Joe Sebastian; Amanda M Crooks; Mehri S McKellar; David M Margolis; Susan A Fiscus; Charles B Hicks; Guido Ferrari; Joseph J Eron
Journal:  AIDS       Date:  2016-11-28       Impact factor: 4.177

9.  Seroprevalence and vaccination coverage of vaccine-preventable diseases in perinatally HIV-1-infected patients.

Authors:  Laura Sticchi; Bianca Bruzzone; Patrizia Caligiuri; Emanuela Rappazzo; Michele Lo Casto; Laura De Hoffer; Giulia Gustinetti; Claudio Viscoli; Antonio Di Biagio
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

10.  Early ART Initiation Improves HIV Status Disclosure and Social Support in People Living with HIV, Linked to Care Within a Universal Test and Treat Program in Rural South Africa (ANRS 12249 TasP Trial).

Authors:  Marion Fiorentino; Marie Nishimwe; Camelia Protopopescu; Collins Iwuji; Nonhlanhla Okesola; Bruno Spire; Joanna Orne-Gliemann; Nuala McGrath; Deenan Pillay; François Dabis; Joseph Larmarange; Sylvie Boyer
Journal:  AIDS Behav       Date:  2020-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.